Printed From BioPortfolio.com
FDA Approves Seattle Genetics’ Adcetris for pcALCL and CD30-Expressing MF
14:01 EST 9 Nov 2017 | Speciality Pharma Journal
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy. Primary cutaneous ALCL and MF are the most common …
Original Article: FDA Approves Seattle Genetics’ Adcetris for pcALCL and CD30-Expressing MF
